Ocuphire Pharma, Inc.

How big is Ocuphire Pharma, Inc.?

As of Jun 18, Ocuphire Pharma, Inc. has a market capitalization of 55.10 million, classifying it as a Micro Cap company, with net sales of 13.65 million and a net profit of -58.61 million over the latest four quarters. The company reported shareholder's funds of 6.72 million and total assets of 36.89 million as of Dec 24.

Market Cap: As of Jun 18, Ocuphire Pharma, Inc. has a market capitalization of 55.10 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Ocuphire Pharma reported net sales of 13.65 million and a net profit of -58.61 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 6.72 million and total assets of 36.89 million.

What does Ocuphire Pharma, Inc. do?

Ocuphire Pharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $4 million and a net loss of $8 million as of March 2025, with a market cap of $55.10 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -660.22%.

Overview: <BR>Ocuphire Pharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 4 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 55.10 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -4.52 <BR>Return on Equity: -660.22% <BR>Price to Book: 10.86<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Ocuphire Pharma, Inc.?

Is Ocuphire Pharma, Inc. overvalued or undervalued?

As of March 8, 2024, Ocuphire Pharma, Inc. is considered risky due to its overvaluation, highlighted by a Price to Book Value of 12.23, negative earnings, a staggering ROE of -660.22%, and a troubling long-term decline of -83.87% over five years, despite recent short-term stock performance.

As of 8 March 2024, the valuation grade for Ocuphire Pharma, Inc. has moved from attractive to risky, indicating a shift in perception regarding its financial health and future prospects. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 12.23 and an EV to Sales ratio of 2.86, which suggest that investors are paying a premium for the stock despite its negative earnings. Additionally, the company's ROE stands at a staggering -660.22%, highlighting significant financial distress.<BR><BR>In comparison to its peers, Ocuphire Pharma, Inc. has a worse EV to EBITDA ratio of -1.08, while CytomX Therapeutics, Inc., which is rated very attractive, boasts an EV to EBITDA of 4.6280. Other risky peers like Aquestive Therapeutics, Inc. show even more concerning metrics with an EV to EBITDA of -12.8252. Despite recent stock performance where Ocuphire outperformed the S&P 500 in the 1-week and 1-month periods, the long-term returns are troubling, with a 5-year decline of -83.87% compared to the S&P 500's gain of 96.61%. This further reinforces the notion that Ocuphire is currently overvalued.

Is Ocuphire Pharma, Inc. technically bullish or bearish?

As of September 2, 2025, Ocuphire Pharma, Inc. has a bullish technical trend with strong indicators, outperforming the S&P 500 in the short term but underperforming over the longer term.

As of 2 September 2025, the technical trend for Ocuphire Pharma, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish. Daily moving averages also indicate a bullish trend. The KST is bullish on a weekly basis and mildly bullish monthly, while the OBV shows bullish signals for both time frames. <BR><BR>In terms of performance, Ocuphire has outperformed the S&P 500 over the past week and month, with returns of 5.67% and 29.57% compared to the S&P 500's 1.05% and 2.33%, respectively. However, the longer-term returns over 1 year, 3 years, and 5 years show underperformance relative to the benchmark.